Physician profile
Darrell R Johnson
NPI 1285682179
$1,919.51
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $514 · 2022: $63.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $413.06 | 2019-2020 | |
| Genentech USA, INC. | $193.87 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $186.30 | 2019-2020 | |
| Amgen INC. | $155.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.20 | 2019-2020 | |
| Lilly USA, LLC | $89.43 | 2019 | |
| Astellas Pharma US INC | $83.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $82.68 | 2019-2020 | |
| Genzyme Corporation | $78.95 | 2019 | |
| Pfizer INC. | $77.80 | 2019-2020 | |
| Channel Medsystems, INC. | $63.84 | 2022 | |
| Celgene Corporation | $51.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.01 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $41.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.49 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.86 | 2019-2020 | |
| Incyte Corporation | $23.38 | 2019 | |
| Aurobindo Pharma USA, INC. | $23.04 | 2019 | |
| Dendreon Pharmaceuticals LLC | $17.37 | 2019 | |
| Daiichi Sankyo INC. | $16.95 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $16.15 | 2019 | |
| Verastem, INC. | $13.69 | 2020 | |
| Array Biopharma INC | $13.25 | 2020 | |
| Mylan Institutional INC. | $13.15 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $11.23 | 2019 | |
| Abbvie INC. | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.